5-bromo-2-((4-fluorophenyl)thio)pyridine | 1247462-49-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 5-bromo-2-((4-fluorophenyl)thio)pyridine
• 英文别名: 5-Bromo-2-(4-fluorophenyl)sulfanylpyridine
• CAS: 1247462-49-2
• 化学式: C₁₁H₇BrFNS
• 分子量: 284.152
• InChiKey: GPQLWZIGRKIAAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-bromo-2-((4-fluorophenyl)thio)pyridine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以50 %的产率得到5-bromo-2-((4-fluorophenyl)sulfonyl)pyridine
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1
• 作为产物：
  描述：

  2-氟-5-溴吡啶 、 对氟苯硫酚 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以25 %的产率得到5-bromo-2-((4-fluorophenyl)thio)pyridine
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1

文献信息

• Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development
  作者：Michael A. Letavic、Leah Aluisio、John R. Atack、Pascal Bonaventure、Nicholas I. Carruthers、Christine Dugovic、Anita Everson、Mark A. Feinstein、Ian C. Fraser、Kenway Hoey、Xiaohui Jiang、John M. Keith、Tatiana Koudriakova、Perry Leung、Brian Lord、Timothy W. Lovenberg、Kiev S. Ly、Kirsten L. Morton、S. Timothy Motley、Diane Nepomuceno、Michele Rizzolio、Raymond Rynberg、Kia Sepassi、Jonathan Shelton

  DOI：10.1016/j.bmcl.2010.05.041

  日期：2010.7

  The pre-clinical characterization of novel aryloxypyridine amides that are histamine H-3 receptor antagonists is described. These compounds are high affinity histamine H-3 ligands that penetrate the CNS and occupy the histamine H-3 receptor in rat brain. Several compounds were extensively pro. led pre-clinically leading to the identification of two compounds suitable for nomination as development candidates. (C) 2010 Elsevier Ltd. All rights reserved.